IP Library Granted Patent US 7,176,218
Granted Patent B2
US 7,176,218 · App. 11/031,623 · Granted Feb 13, 2007

Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,218
App. No.
11/031,623
Granted
Feb 13, 2007
Kind
B2
Abstract

The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.

Claims (40)

1. A compound selected from

(3R,4S,3′R)-6-[4-(4-Amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester

and pharmaceutically acceptable salts thereof.

2. A compound selected from

(3S,4R,3′R)-6-[4-(4-Amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester

and pharmaceutically acceptable salts thereof.

3. A compound selected from

(3R,4S,3′S)-6-[4-(4-Amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester

and pharmaceutically acceptable salts thereof.

4. A compound selected from

(3S,4R,3′S)-6-[4-(4-Amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester

and pharmaceutically acceptable salts thereof.

5. The composition according to claim 1 wherein the compound is a dihydrochloride salt form.

6. The composition according to claim 2 wherein the compound is a dihydrochloride salt form.

7. The composition according to claim 3 wherein the compound is a dihydrochloride salt form.

8. The composition according to claim 4 wherein the compound is a dihydrochloride salt form.

9. A composition comprising the compound according to claim 1 wherein the compound is present in at least about 90% stereoisomeric excess.

10. A composition comprising the compound according to claim 2 wherein the compound is present in at least about 90% stereoisomeric excess.

11. A composition comprising the compound according to claim 3 wherein the compound is present in at least about 90% stereoisomeric excess.

12. A composition comprising the compound according to claim 4 wherein the compound is present in at least about 90% stereoisomeric excess.

13. A composition comprising the compound according to claim 5 wherein the compound is present in at least about 90% stereoisomeric excess.

14. A composition comprising the compound according to claim 6 wherein the compound is present in at least about 90% stereoisomeric excess.

15. A composition comprising the compound according to claim 7 wherein the compound is present in at least about 90% stereoisomeric excess.

16. A composition comprising the compound according to claim 8 wherein the compound is present in at least about 90% stereoisomeric excess.

17. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

18. A composition comprising the compound according to claim 2 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

19. A composition comprising the compound according to claim 3 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

20. A composition comprising the compound according to claim 4 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

21. A composition comprising the composition according to claim 5 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

22. A composition comprising the composition according to claim 6 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

23. A composition comprising the composition according to claim 7 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

24. A composition comprising the composition according to claim 8 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

25. A composition comprising the compound according to claim 9 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

26. A composition comprising the compound according to claim 10 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

27. A composition comprising the compound according to claim 11 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

28. A composition comprising the compound according to claim 12 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

29. A composition comprising the composition according to claim 13 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

30. A composition comprising the composition according to claim 14 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

31. A composition comprising the composition according to claim 15 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

32. A composition comprising the composition according to claim 16 and a pharmaceutically acceptable excipient, adjuvant, carrier, or solvent.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: ARMETHEON, INC.
To: NARONAPRIDE, LLC
Reel/Frame 040699/0559 →
CHANGE OF NAME Recorded Dec 9, 2016
From: NARONAPRIDE, LLC
To: RENEXXION, LLC
Reel/Frame 040876/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2013
From: DRUZGALA, PASCAL J.
To: ARMETHEON, INC.
Reel/Frame 030816/0442 →
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2013
From: AYER CAPITAL PARTNERS MASTER FUND, L.P.; MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; AYER CAPITAL PARTNERS KESTREL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC
To: ARYX THERAPEUTICS, INC.
Reel/Frame 029767/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2012
From: ARYX THERAPEUTICS, INC.
To: ARMETHEON, INC.
Reel/Frame 029080/0290 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE WHICH SHOULD BE ARYX THERAPEUTICS PREVIOUSLY RECORDED ON REEL 016464 FRAME 0278. ASSIGNOR(S) HEREBY CONFIRMS THE NAME OF THE ASSIGNEE SHOULD HAVE BEEN ARYX THERAPEUTICS. THE ASSIGNEE NAME SHOULD NOT HAVE HAD INC.. Recorded Aug 31, 2012
From: IRWIN, IAN; PALME, MONICA; BECKER, CYRUS
To: ARYX THERAPEUTICS
Reel/Frame 028890/0001 →
SECURITY AGREEMENT Recorded Oct 18, 2010
From: ARYX THERAPEUTICS, INC.
To: AYER CAPITAL PARTNERS MASTER FUND, L.P.; MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; AYER CAPITAL PARTNERS KESTREL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC
Reel/Frame 025150/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2010
From: ARYX THERAPEUTICS
To: ARYX THERAPEUTICS, INC.
Reel/Frame 024026/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2005
From: IRWIN, IAN; PALME, MONICA; BECKER, CYRUS
To: ARYX THERAPEUTICS, INC.
Reel/Frame 016464/0278 →